Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone

New England Journal of Medicine

Volumn 338, Issue 7, 1998, Pages 416-422

  Rösler, Ariel ^a,c   Witztum, Eliezer ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN DERIVATIVE; TRIPTORELIN;

ADULT; ARTICLE; BONE DENSITY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; HORMONAL REGULATION; HOT FLUSH; HUMAN; HYPOPHYSIS GONAD SYSTEM; IMPOTENCE; MALE; PRIORITY JOURNAL; RATING SCALE; SEXUAL BEHAVIOR; SEXUAL DEVIATION; TESTOSTERONE RELEASE; TREATMENT OUTCOME;

ADULT; BONE DENSITY; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; IMPOTENCE; LUTEINIZING HORMONE; MALE; PARAPHILIAS; TESTIS; TESTOSTERONE; TREATMENT OUTCOME; TRIPTORELIN;

EID: 2642683170     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199802123380702     Document Type: Article

References (43)

1. Sexual offenses. In: Bancroft J. Human sexuality and its problems. 2nd ed. Edinburgh, Scotland: Churchill Livingstone, 1989:664-731.
2. Child abuse and neglect: critical first steps in response to a national emergency. Washington, D.C.: Advisory Board on Child Abuse and Neglect, 1990.
3. Report of the Committee on Sexual Offenses against Children and Youths: sexual offenses against children in Canada. Ottawa, Ont.: Ministry of Supply and Services Canada, 1984.
4. Glaser B. Paedophilia: the public health problem of the decade. Research and public policy series. No. 12. Canberra: Australian Institute of Criminology, 1997:4-13.
5. Baker AW, Duncan SP. Child sexual abuse: a study on prevalence in Great Britain. Child Abuse Negl 1985;9:457-67
6. Kutchinsky B. Pornography and its effects in Denmark and the United States. Comp Soc Res 1985;8:301-30.
7. Vandemeulebroucke M. Un justice plus humaine pour l'enfance violée. Le Soir. January 14-15, 1995:1.
8. Idem. Comment soigner les pédophiles? Le Soir. January 14-15, 1995: 27.
9. Abel GG. Paraphilias. In Kaplan HI, Sadock BJ, eds. Comprehensive textbook of psychiatry/V. 5th ed. Vol. 1. Baltimore: Williams & Wilkins, 1989:1069-85.
10. Money J. Paraphilias: phenomenology and classification. Am J Psychother 1984;38:164-79.
11. Finkelhor D, Araji S. Explanations of pedophilia: a four factor model. J Sex Res 1986;22:145-61.
12. Diagnosis and statistical manual of mental disorders. 4th ed.: DSM-IV. Washington, D.C.: American Psychiatric Association, 1994:527-8.
13. Heim N, Hursch CJ. Castration for sex offenders: treatment or punishment? A review and critique of recent European literature. Arch Sex Behav 1979;8:281-304.
14. Marshall WL, Barbaree HE. The long-term evaluation of a behavioral treatment program for child molesters. Behav Res Ther 1988;26:499-511.
15. Richer M, Crismon ML. Pharmacotlierapy of sexual offenders. Ann Pharmacother 1993;27:316-20.
16. Stein DJ, Hollander E, Anthony DT, et al. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. J Clin Psychiatry 1992;53:267-71.
17. Money J. Treatment guidelines: antiandrogen and counseling of paraphilic sex offenders. J Sex Marital Ther 1987;13:219-23.
18. Meyer WJ III, Cole C, Emory E. Depo provera treatment for sex offending behavior: an evaluation of outcome. Bull Am Acad Psychiatry Law 1992;20:249-59.
19. Neumann F, Kalmus J. Cyproterone acetate in the treatment of sexual disorders: pharmacological base and clinical experience. Exp Clin Endocrinol 1991;98:71-80.
20. Bradford JMW, Pawlak A. Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias. Arch Sex Behav 1993;22:383-402.
21. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogues. N Engl J Med 1990;324:93-103.
22. Thibaut F, Cordier B, Kuhn JM. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand 1993;87:445-50.
23. Zachmann M, Prader A, Kind HP, Hatliger H, Budligcr H. Testieular volume during adolescence: cross-sectional and longitudinal studies. Helv Pediatr Acta 1974;29:61-72.
24. Battle CC, Imber SD, Hoehn-Saric R, Nash ER, Frank JD. Target complaints as criteria of improvement. Am J Psychothcr 1966;20:184-92.
25. Bancroft J, Tennent G, Loucas K, Cass J. The control of deviant sexual behavior by drugs. I. Behavioural changes following oestrogens and antiandrogens. Br J Psychiatry 1974;125:310-5.
26. Rosier A. Steroid 17/3-hydroxysteroid dehydrogcnasc deficiency in man: an inherited form of male pseudohermaphroditisni. T Steroid Biochem Mol Biol 1992;43:989-1002.
27. Cohen J, Cohen P. Applied multiple regression/correlation analysis of the behavioral sciences. 2nd ed. Hillsdale, N.J.: Lawrence Erlbaum, 1983: 172-3.
28. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry 1996;153:974-84.
29. Cunningham GR, Hirshkowitz M, Kovenman SG, Karacan I. Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Mctab 1990;70:792-7.
30. Salmimies P, Kockott G, Pirke KM, Vogt HJ, Schill WB. Effects of testosterone replacement on sexual behavior in hypogonadal men. Arch Sex Behav 1982;11:345-53.
31. Hirsch D, Kovatz S, Bernheim J, Shenkman L. Fatal fulminant hepatitis from cyproterone acetate. Isr J Med Sci 1994;30:238-40.
32. Cundy T, Farquhar CM, Cornish J, Reid IR. Short-term effects of high dose oral medroxyprogcsterone acetate on bone density in premenopausal women. J Clin Endocrinol Metab 1996;81:1014-7.
33. Allolio B, Kcftel D, Deuss U, Winkelmann W. Behandlung sexueller Verhaltensstörungen mit LH-RH-Superagonisten. Dtsch Med Wochenschr 1985;110:1952.
34. Rousseau L, Couture M, Dupont A, Labrie F, Couture N. Effect of combined androgen blockade with an LHRH agonist and flutamide in one severe case of male exhibitionism. Can J Psychiatry 1990;35:338-41.
35. Dickey R. The management of a case of treatment-resistant paraphilia with a long-acting LHRH agonist. Can J Psychiatry 1992;37:567-9.
36. Cooper AJ, Cernovsky ZZ. Comparison of cyproterone acetate (CPA) and leuprolide acetate (LHRH agonist) in a chronic pedophile: a clinical case study. Biol Psychiatry 1994;36:269-71.
37. Thibaut F, Cordier B, Kuhn JM. Gonadotropin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment? Psychoneuroendocrinology 1996;21:411-9.
38. Loosen PT, Purdon SE, Pavlou SN, Effects on behavior of modulation of gonadal function in men with gonadotropin-relcasing hormone antagonists. Am J Psychiatry 1994;151:271-3.
39. Kadar T, Telegdy G, Serially AV. Behavioral effects of centrally administered LH-RH agonist in rats. Physiol Behav 1992;51:601-5.
40. Moss RL, Dudley CA. Luteinizing hormone-releasing hormone (LHRH): peptidergic signals in the neural integration of female reproductive behavior. In: Lakoski JM, Perez-Polo JR, Rassin DK, eds. Neural control of reproductive function. Vol. 50 of Neurology and neurobiology. New York: Alan R. Liss, 1989:485-99.
41. 6-GnRH). J Clin Endocrinol Metab 1993;76:288-90.
42. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
43. Prentky R, Burgess AW. Rehabilitation of child molesters: a cost-benefit analysis. Am J Orthopsychiatry 1990;60:108-17.